These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36142631)

  • 1. Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre.
    Vari S; Riva F; Onesti CE; Cosimati A; Renna D; Biagini R; Baldi J; Zoccali C; Anelli V; Annovazzi A; Covello R; Ascione A; Casini B; Ferraresi V
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.
    Hasenfratz M; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Roitman PD; Aponte-Tinao LA; Lehner B; Möller P; Mechtersheimer G; Barth TFE
    Sci Rep; 2021 Mar; 11(1):5709. PubMed ID: 33707617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drivers underpinning the malignant transformation of giant cell tumour of bone.
    Fittall MW; Lyskjaer I; Ellery P; Lombard P; Ijaz J; Strobl AC; Oukrif D; Tarabichi M; Sill M; Koelsche C; Mechtersheimer G; Demeulemeester J; Tirabosco R; Amary F; Campbell PJ; Pfister SM; Jones DT; Pillay N; Van Loo P; Behjati S; Flanagan AM
    J Pathol; 2020 Dec; 252(4):433-440. PubMed ID: 32866294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symplastic/pseudoanaplastic giant cell tumor of the bone.
    Sarungbam J; Agaram N; Hwang S; Lu C; Wang L; Healey J; Hameed M
    Skeletal Radiol; 2016 Jul; 45(7):929-35. PubMed ID: 27020452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
    Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
    Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
    Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
    Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
    BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
    Yamamoto H; Ishihara S; Toda Y; Oda Y
    Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
    Tsukamoto Y; Futani H; Kihara T; Watanabe T; Kumanishi S; Matsuo S; Hirota S; Ueda T; Yamamoto H; Yoshiya S
    Pathol Res Pract; 2018 Sep; 214(9):1504-1509. PubMed ID: 29970305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiological findings of denosumab treatment for giant cell tumours of bone.
    van Langevelde K; McCarthy CL
    Skeletal Radiol; 2020 Sep; 49(9):1345-1358. PubMed ID: 32335707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
    Tsukamoto S; Righi A; Vanel D; Honoki K; Donati DM; Errani C
    Jpn J Clin Oncol; 2017 Nov; 47(11):1090-1096. PubMed ID: 29048579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
    Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
    Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
    Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
    Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current concepts in the treatment of giant cell tumour of bone.
    van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
    Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
    Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
    Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
    Ratnagiri R; Uppin S
    J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
    Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
    Abu-Zaid A; Alaqaili SI; Ahmad SO; Bin Hazzaa I; Alharbi H
    Gulf J Oncolog; 2019 May; 1(30):67-75. PubMed ID: 31242985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
    Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
    Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.